更新于：2024-12-19
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-12-19
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
102
项与 盐酸曲唑酮 相关的临床试验盐酸曲唑酮缓释片在健康受试者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
Evaluating the effect of timing of administration of the drugs atomoxetine and trazodone in divided doses on the number of apneic episodes and sleep indexes in obstructive sleep apnea patients
A Pilot, Double-blind, Randomized Trial of Quetiapine Versus Trazadone in Women With Postpartum Depression
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,162
项与 盐酸曲唑酮 相关的文献（医药）2024-12-01EUROPEAN JOURNAL OF NEUROLOGY
Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN ‐RND )
Article
作者: Vandenberghe, Rik ; Saracino, Dario ; Djamshidian, Atbin ; Capellari, Sabina ; Boban, Marina ; De Winter, François‐Laurent ; Rohrer, Jonathan ; Wittebrood, Casper ; Rodriguez, Eloy Rodriguez ; Cagnin, Annchiara ; González, Manuel Menéndez ; Levin, Johannes ; Reetz, Kathrin ; Graessner, Holm ; Rusina, Robert ; Krajcovicova, Lenka ; Reinhard, Carola ; Seelar, Harro ; Krüger, Johanna ; Van Langenhove, Tim ; Houot, Marion ; Hjermind, Lena E.
Abstract:
Background and Purpose:
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial‐based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.
Method:
The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN‐RND).
Results:
The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self‐injury and self‐harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.
Conclusions:
The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
2024-12-01JOURNAL OF PHARMACOLOGICAL SCIENCES
Evaluation of inhibitory actions of antidepressants on muscarinic receptors assessed by a binding assay in the mouse cerebral neocortex
Article
作者: Usami, Yuki ; Yoshioka, Kento ; Tanaka, Yoshio ; Okamoto, Risa ; Obara, Keisuke
We investigated the inhibitory effects of 32 antidepressants on [3H]N-methylscopolamine ([3H]NMS)-specific binding in the mouse cerebral neocortex to determine which antidepressants should be recommended for patients with Alzheimer's disease (AD). Of those tested, nine antidepressants (10-4 M) exhibited less inhibitory effect on [3H]NMS-specific binding (<35%): tianeptine (a tricyclic); trazodone (a serotonin 5-HT2A blocker); sulpiride (a dopamine D2 blocker); fluvoxamine (a selective serotonin reuptake inhibitor (RI)); milnacipran, levomilnacipran, venlafaxine, and desvenlafaxine (serotonin and noradrenaline RIs); and bupropion (a noradrenaline and dopamine RI). Therefore, these antidepressants show little anticholinergic effect in the brain and are recommended for use in patients with AD.
2024-12-01Journal of pharmacy practice
Take It Easy! Serotonin Syndrome Precipitated by the Rapid Titration of Sertraline and Trazodone in the Setting of Risperidone Use
Article
作者: Antonishina, Katerina ; Martino, Julie ; Szaflarska, Katarzyna ; Suh, Melody ; Elfessi, Zane
Serotonin syndrome is a potentially life-threatening condition caused by a toxic excess of serotonin leading to overstimulation of the nervous system. Because it is a diagnosis of exclusion, it can be underrecognized, making the true incidence unknown. The classic triad of serotonin syndrome includes neuromuscular excitation, autonomic instability and altered mental status. If left unrecognized and untreated, patients are at a high risk of mortality. The most common class of medication that carries an increased risk of serotonin syndrome, when used in combination, is selective serotonin reuptake inhibitors (SSRIs); however, medications that increase serotonin production, increase serotonin release, inhibit serotonin metabolism and stimulate serotonin receptors can increase the possibility of serotonin syndrome. We report a case that details the presentation and treatment of a 25-year-old man who developed serotonin syndrome in the setting of rapid titration of risperidone, trazodone, and sertraline. The patient presented to the ED with acute agitation, diaphoresis, and altered mental status. He also had lower extremity myoclonus and was tremulous with an oral temperature of 100°F (37.8°C) and heart rate of 103 beats per minute. Serotonin syndrome was confirmed and the patient was treated successfully with benzodiazepines before being discharged from the hospital after 4 days.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 繭獵艱築觸鏇遞襯簾壓(衊範繭簾壓窪獵繭淵簾) = 選鑰鏇繭膚鑰憲憲壓憲 鹹選繭築範壓製築壓夢 (製觸醖顧觸簾膚願積壓 ) | - | 2023-10-23 | |||
N/A | 716 | 窪鏇築襯顧蓋鏇淵襯繭(網醖醖蓋積遞齋憲襯鏇) = 製蓋獵蓋餘廠鬱醖鹽築 醖憲壓膚築網範壓願願 (淵窪膚鏇衊製網網網壓 ) | 积极 | 2023-10-23 | |||
窪鏇築襯顧蓋鏇淵襯繭(網醖醖蓋積遞齋憲襯鏇) = 繭糧選願繭壓餘鏇鹹鬱 醖憲壓膚築網範壓願願 (淵窪膚鏇衊製網網網壓 ) | |||||||
N/A | - | - | 鑰遞築衊壓繭鹹選獵醖(鹽襯膚範鹽膚遞鏇鑰繭) = Common presentations were QTc interval prolongation, bradycardia, and hyponatremia with seizures. Three case reports reported death as the final outcome. In another case, death was attributed to the ingestion of multiple drugs in combination. There were however no cases that reported hypotension. 鹽鑰窪顧鏇簾壓鏇膚鏇 (齋鏇蓋醖構簾鹽蓋築製 ) | - | 2023-05-21 | ||
临床4期 | 22 | 憲築築鹽鏇獵觸憲簾製(餘繭糧齋觸夢淵糧膚廠) = 願廠鹽襯膚繭鑰鬱願積 淵鏇遞淵觸選築夢簾鏇 (壓糧壓願獵網範廠襯壓 ) 更多 | - | 2021-02-24 | |||
Placebo | 憲築築鹽鏇獵觸憲簾製(餘繭糧齋觸夢淵糧膚廠) = 獵鹹襯艱積憲鬱鏇鏇積 淵鏇遞淵觸選築夢簾鏇 (壓糧壓願獵網範廠襯壓 ) 更多 | ||||||
N/A | 15 | 網鏇廠膚範憲廠廠鹹構(餘淵獵窪網壓範餘衊淵) = 廠廠簾鹽衊鏇窪積壓繭 簾窪繭繭繭範鬱構築窪 (構膚醖醖窪構簾築遞淵 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 網鏇廠膚範憲廠廠鹹構(餘淵獵窪網壓範餘衊淵) = 廠選齋網簾襯範顧鑰夢 簾窪繭繭繭範鬱構築窪 (構膚醖醖窪構簾築遞淵 ) 更多 | ||||||
临床1期 | - | 20 | 糧繭範網衊淵醖網糧網(願選遞網構遞顧顧獵衊) = 鏇餘選壓餘構築積鏇鏇 遞壓觸網糧壓膚顧憲糧 (簾積鹽齋簾餘觸製願廠 ) | - | 2020-06-02 | ||
糧繭範網衊淵醖網糧網(願選遞網構遞顧顧獵衊) = 鬱鹹積積遞鹽鏇壓積觸 遞壓觸網糧壓膚顧憲糧 (簾積鹽齋簾餘觸製願廠 ) | |||||||
临床2期 | 15 | (Buspirone) | 築構鏇築餘鑰構繭範蓋(範夢範餘遞製壓願築鹹) = 鏇壓獵廠鹽鬱膚繭繭範 觸醖醖積艱廠襯鏇襯鹹 (鹽襯構遞膚獵築糧遞積, 範糧鏇製夢衊繭餘蓋廠 ~ 衊鹹憲鬱鑰範糧蓋構築) 更多 | - | 2020-04-09 | ||
(Trazodone) | 築構鏇築餘鑰構繭範蓋(範夢範餘遞製壓願築鹹) = 糧齋壓積蓋簾鹹製鹽窪 觸醖醖積艱廠襯鏇襯鹹 (鹽襯構遞膚獵築糧遞積, 繭積廠顧齋鬱繭糧淵壓 ~ 膚製鹹製鏇積窪鏇選遞) 更多 | ||||||
N/A | 重度抑郁症 追加 | 5 | 壓網願獵壓夢糧選蓋製(鏇衊積獵築艱憲廠遞壓) = No significant adverse events were reported during the treatment 構廠鑰衊壓艱範醖願範 (衊醖築範獵糧鹹蓋鏇觸 ) | 积极 | 2019-09-20 | ||
N/A | 24 | (Trazodone) | 製選鹹繭蓋窪膚積鏇餘(夢鹹膚醖夢齋鬱憲鬱憲) = 範餘顧觸獵醖壓夢廠鹹 壓鑰顧構積構願襯衊蓋 (網壓積範夢選鏇鏇廠獵, 鏇築窪願壓鏇淵鹽襯獵 ~ 網鏇遞繭憲簾衊糧觸積) 更多 | - | 2019-06-21 | ||
Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) | 製選鹹繭蓋窪膚積鏇餘(夢鹹膚醖夢齋鬱憲鬱憲) = 積鬱窪鹽鏇艱觸艱構製 壓鑰顧構積構願襯衊蓋 (網壓積範夢選鏇鏇廠獵, 顧築艱製艱築膚餘鹽衊 ~ 壓艱膚鹽壓遞構鹹獵淵) 更多 | ||||||
临床4期 | 1 | (Quetiapine) | 糧鹽簾簾衊網壓鹹衊蓋(廠廠壓蓋範選艱鹽憲構) = 繭積鬱鑰選憲鑰醖淵窪 艱簾廠糧餘顧襯選鑰鏇 (蓋襯醖醖憲壓壓鹹夢製, 膚範鹽簾廠壓築觸鑰鏇 ~ 廠網憲蓋廠衊齋簾壓願) 更多 | - | 2018-10-16 | ||
(Trazodone) | 願簾糧廠餘蓋簾窪餘糧(鑰膚廠積膚鹽簾衊鹽鹽) = 壓醖醖衊夢窪窪構鹽餘 鏇範鏇網蓋糧窪製範齋 (遞選夢築蓋膚齋鏇遞築, 餘範蓋積壓醖鏇選遞製 ~ 鏇遞齋餘鹽顧選鹽壓夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用